Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells

We have recently shown that Thymoquinone (TQ) is an antineoplastic drug that induces p53-dependent apoptosis in human colon cancer cells. This study evaluated the antiproliferative and pro-apoptotic effects of TQ in two human osteosarcoma cell lines with different p53 mutation status. TQ decreased cell survival dose-dependently and, more significantly, in p53-null MG63 cells (IC50=17μM) than in p53-mutant MNNG/HOS cells (IC50=38μM). Cell viability was reduced more selectively in MG63 tumor cells than in normal human osteoblasts. Flow cytometric analysis showed that TQ induced a much greater increase in the PreG1 (apoptotic) cell population, but no cell cycle arrest in MG63. G2/M arrest in MNNG/HOS cells was associated with p21WAF1 up-regulation. Using three DNA damage assays, TQ was confirmed to result in a significantly greater extent of apoptosis in p53 null MG63 cells. Although the Bax/Bcl-2 ratios were not differentially modulated in both cell lines, the mitochondrial pathway appeared to be involved in TQ-induced apoptosis in MG63 by showing the cleavage of caspases-9 and -3. Oxidative stress and mitochondrial O2•− generation in isolated rat mitochondria were enhanced by TQ as measured by the dose-dependent reduction in aconitase enzyme activity. TQ-induced oxidative damage, reflected by an increase in γ-H2AX foci and increased protein expression levels of γ-H2AX and the DNA repair enzyme, NBS1, was more pronounced in MNNG/HOS than in MG63. We suggest that the resistance of MNNG/HOS cells to drug-induced apoptosis is caused by the up-regulation of p21WAF1 by the mutant p53 (transcriptional activity was shown by p53 siRNA treatment) which induces cell cycle arrest and allows to repair DNA damage. Collectively, these findings show that TQ induces p53-independent apoptosis in human osteosarcoma cells. As the loss of p53 function is frequently observed in osteosarcoma patients, our data suggest the potential clinical usefulness of TQ for the treatment of these malignancies.

[1]  O. Badary,et al.  Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. , 1997, Canadian journal of physiology and pharmacology.

[2]  Yigong Shi,et al.  Molecular mechanisms of caspase regulation during apoptosis , 2004, Nature Reviews Molecular Cell Biology.

[3]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[4]  O. Badary,et al.  Thymoquinone Is a Potent Superoxide Anion Scavenger , 2003, Drug and chemical toxicology.

[5]  A. Al-Majed,et al.  Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. , 2006, European journal of pharmacology.

[6]  T. Tsuruo,et al.  p21Waf1/cip1 acts in synergy with bcl‐2 to confer multidrug resistance in a camptothecin‐selected human lung‐cancer cell line , 1999, International journal of cancer.

[7]  P. Crooks,et al.  Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes , 2004, Anti-cancer drugs.

[8]  R. Schneider-Stock,et al.  Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. , 2004, International journal of oncology.

[9]  P. Dudrick,et al.  In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. , 2003, International journal of oncology.

[10]  M. Martínez-Lorenzo,et al.  Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.

[11]  P. Crooks,et al.  The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. , 1998, Anticancer research.

[12]  P. R. Gardner Aconitase: sensitive target and measure of superoxide. , 2002, Methods in enzymology.

[13]  G. Núñez,et al.  Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.

[14]  F. Alt,et al.  Functional Interaction of H2AX, NBS1, and p53 in ATM-Dependent DNA Damage Responses and Tumor Suppression , 2005, Molecular and Cellular Biology.

[15]  A. A. Starkov,et al.  Mitochondrial metabolism of reactive oxygen species , 2005, Biochemistry (Moscow).

[16]  W. Kunz,et al.  [Use of "cycling" technic for random quantitative determination of the degree of reduction of NAD and NADP system in rat liver mitochondria with continuous recording of the measurements]. , 1970, Acta biologica et medica Germanica.

[17]  R. Youle,et al.  Control of mitochondrial permeability by Bcl-2 family members. , 2004, Biochimica et biophysica acta.

[18]  H. Koeffler,et al.  Rearrangement of the p53 gene in human osteogenic sarcomas. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Uchida,et al.  Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines. , 2003, Oncology reports.

[20]  R. Schneider-Stock,et al.  Thymoquinone: a promising anti-cancer drug from natural sources. , 2006, The international journal of biochemistry & cell biology.

[21]  G. Wani,et al.  Thymoquinone induces apoptosis through activation of caspase‐8 and mitochondrial events in p53‐null myeloblastic leukemia HL‐60 cells , 2005, International journal of cancer.

[22]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Wahl,et al.  c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.

[24]  G. Sheu,et al.  Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. , 2004, European journal of pharmacology.